

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **FBXO31 RABBIT PAB**

货号: S222021

产品全名: FBXO31 兔多抗

基因符号 FBX14; Fbx31; MRT45; FBXO14; pp2386
UNIPROT ID: Q5XUX0 (Gene Accession - NP\_079011)

背景: This gene is a member of the F-box family. Members are classified into three classes according to the substrate interaction domain, FBW for WD40 repeats, FBL for leucing-rich repeats, and FBXO for other domains. This protein, classified into the last category because of the lack of a recognizable substrate binding domain, has been proposed to be a component of the SCF ubiquitination complex. It is thought to bind and recruit substrate for ubiquitination and degradation. This protein may have a role in regulating the cell cycle as well as dendrite growth and neuronal migration. Alternative splicing results in multiple transcript variants.

抗原: Synthetic peptide of human FBXO31

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-50; ELISA: 500-1000


种属反应性: Rabbit 克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Cancer, Cell Biology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 222021(FBXO31 Antibody) at a dilution of 1/20(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 222021(Anti-FBXO31 Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffinembedded Human colorectal cancer tissue using 222021(Anti-FBXO31 Antibody) at a dilution of 1/20.



In comparision with the IHC on the left, the same paraffin-embedded Human colorectal cancer tissue is first treated with synthetic peptide and then with D263898(Anti-FBXO31 Antibody) at dilution 1/20.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010